S. Chan

Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh A Liver Function: A Proof-Of-Concept Study

M. Kudo, Y. Minami, S. Hagiwara, 2019, Cancers.

TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance

Nathalie Wong, W. Yeo, N. Wong, 2009, International journal of cancer.

Pembrolizumab in patients with previously treated advanced hepatocellular carcinoma: Phase 2 KEYNOTE-224 study

M. Kudo, A. Zhu, R. Finn, 2016 .

67O Outcomes in the Asian subgroup of the phase III HIMALAYA study of tremelimumab (T) plus durvalumab (D) in unresectable hepatocellular carcinoma (uHCC)

P. Sunpaweravong, J. Furuse, G. Abou-Alfa, 2022, Annals of Oncology.

PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma

R. Holcombe, G. Abou-Alfa, M. Mulcahy, 2011, Cancer Chemotherapy and Pharmacology.

Health-related quality of life (HRQoL) impact of pembrolizumab (pembro) versus best supportive care (BSC) in previously systemically treated patients (pts) with advanced hepatocellular carcinoma (HCC): KEYNOTE-240

M. Kudo, A. Zhu, R. Finn, 2019, Annals of Oncology.

TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance

W. Yeo, N. Wong, P. B. Lai, 2009, International journal of cancer.

Significant efficacy in a phase 2 study of NKTR-102, a novel polymer conjugate of Irinotecan, in patients with pre-treated metastatic breast cancer (MBC)

E. Perez, J. Hamm, A. Awada, 2010 .